AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amgen Inc (AMGN) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has shown strong financial performance in the latest quarter and has potential long-term growth catalysts, the current technical indicators and trading sentiment do not suggest an optimal entry point. Additionally, insider selling and the lack of significant positive momentum in the stock price further support a hold recommendation.
The MACD histogram is negative (-2.512) and contracting, indicating weak momentum. RSI is neutral at 39.778, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (357.579), with resistance at 368.287 and support at 346.872.
Amgen's financials for Q4 2025 showed strong YoY growth in revenue (8.58%), net income (112.60%), and EPS (112.07%). Gross margin also improved to 72.88%. Analysts highlight potential long-term growth from new drugs and mechanisms targeting Myasthenia Gravis and other conditions.
Insiders are selling heavily, with a 475.47% increase in selling activity over the last month. The stock has run up about 35% over the past six months, and some analysts believe it is fairly valued at current levels. Technical indicators do not show strong upward momentum.
Amgen's Q4 2025 financials were strong, with revenue increasing to $9.87 billion (up 8.58% YoY), net income rising to $1.33 billion (up 112.60% YoY), and EPS growing to 2.46 (up 112.07% YoY). Gross margin improved to 72.88%, up 10.84% YoY.
Analysts have mixed views. Wells Fargo raised its price target to $390, citing upside potential from new drugs, while Jefferies initiated coverage with a Hold rating and a $350 price target, considering the stock fairly valued. Piper Sandler and TD Cowen remain bullish with price targets of $432 and $420, respectively, while Freedom Capital downgraded the stock to Hold, citing fair valuation.
